UPDATE: Wedbush Raises PT to $20 on Celldex Therapeutics on Rindopepimut Outlook
Wedbush maintained Celldex Therapeutics (NASDAQ: CLDX) with an Outperform rating and raised the price target from $8.00 to $20.00.
Wedbush analyst Gregory R. Wade noted, "We are increasing our price target to $20 from $8 based upon revised launch and peak penetration assumptions as emerging data to suggest a more targeted clinical path for both for rindopepimut and CDX-011. We have increased our peak penetration rate and duration of therapy in the front-line setting for rindopepimut from 45% and 9 cycles to, 65% and 18 cycles, respectively. We now see worldwide peak sales of rindopepimut north of $1 billion."
Celldex Therapeutics closed at $11.89 on Monday.
Latest Ratings for CLDX
|Mar 2015||Cantor Fitzgerald||Maintains||Buy|
|Sep 2014||Cowen & Company||Initiates Coverage on||Outperform|
© 2015 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.